Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
|
CN |
|
C
|
Cetus Capital Acquisition Corp
NASDAQ:CETU
|
TW |
|
G
|
GeneSystem Co Ltd
KOSDAQ:363250
|
KR |
|
ENB Financial Corp
OTC:ENBP
|
US |
|
Slavneft' Yaroslavnefteorgsintez PAO
MOEX:JNOS
|
RU |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Chengdu Olymvax Biopharmaceuticals Inc's stock price target?
Not Available
Chengdu Olymvax Biopharmaceuticals Inc doesn't have any price targets made by Wall Street professionals.
What is Chengdu Olymvax Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
22%
For the last 5 years the
compound annual growth rate for
Chengdu Olymvax Biopharmaceuticals Inc's revenue is
27%.
The projected
CAGR
for the next 3 years is
22%.
What is Chengdu Olymvax Biopharmaceuticals Inc's Operating Income forecast?
Projected CAGR
109%
The
compound annual growth rate
of Chengdu Olymvax Biopharmaceuticals Inc's operating income for the next 2 years is
109%.
What is Chengdu Olymvax Biopharmaceuticals Inc's Net Income forecast?
Projected CAGR
40%
The
compound annual growth rate
of Chengdu Olymvax Biopharmaceuticals Inc's net income for the next 3 years is
40%.
